公开(公告)号：US20220073525A1

公开(公告)日：2022-03-10

申请号：US17417805

申请日：2019-12-27

Applicant: FORMA Therapeutics, Inc.

Inventor： Alexandre Joseph Buckmelter ,  Justin Andrew Caravella ,  Jian Lin ,  Edward L. Fritzen

IPC: C07D487/04

Abstract: This disclosure relates to modulating ubiquitin specific protease 1 (USP1) and provides novel chemical compounds useful as inhibitors of USP1, as well as various uses of these compounds. USP1 inhibiting compounds are useful in the treatment of diseases and disorders associated with USP1, such as cancer.

公开(公告)号：US11267805B2

公开(公告)日：2022-03-08

申请号：US17006317

申请日：2020-08-28

Applicant: FORMA Therapeutics, Inc.

Inventor： George P. Luke ,  Stephen Hubbs ,  Matthew W. Martin ,  Shawn E. R. Schiller ,  Robert Wenslow ,  Yawei Shi ,  Jun Huang

IPC: C07D403/10 ,  A61K31/665

Abstract: The present disclosure reports solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone:

公开(公告)号：US11254674B2

公开(公告)日：2022-02-22

申请号：US16946159

申请日：2020-06-08

Applicant: FORMA Therapeutics, Inc.

Inventor： Shawn E. R. Schiller ,  Torsten Herbertz ,  Hongbin Li ,  Bradford Graves ,  Steven Mischke ,  Angela West ,  Jennifer R. Downing ,  Anna Ericsson

IPC: C07D471/04

Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

公开(公告)号：US11247987B2

公开(公告)日：2022-02-15

申请号：US16753439

申请日：2018-10-05

Applicant: FORMA Therapeutics, Inc.

Inventor： Justin Caravella ,  Bingsong Han ,  Cuixian Liu ,  Stephanos Ioannidis ,  Alexandre Joseph Buckmelter ,  David James Richard ,  Matthew W. Martin ,  Steven Mischke ,  Scot Mente

IPC: C07D417/04 ,  C07D417/12 ,  C07C261/04 ,  C07D231/40 ,  C07D241/04 ,  C07D265/30 ,  C07D277/46 ,  C07D277/56

Abstract: The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Protease 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities. The chemical entities as disclosed herein can be useful in the treatment of a disease, disorder, or condition involving mitochondrial dysfunction, including neurodegenerative diseases, motor neuron diseases, metabolic disorders, and cancers, among other ailments. Chemical entities disclosed herein include compounds of Formula (II): wherein A, R2, R3, R4, Ra, Rc, Rd, Re, Rf, and m are defined herein.

公开(公告)号：US11013734B2

公开(公告)日：2021-05-25

申请号：US16526593

申请日：2019-07-30

Applicant: FORMA Therapeutics, Inc.

Inventor： Patrick F. Kelly ,  Alan Collis ,  Jeff Davis ,  Duncan Walker ,  Susan Ashwell ,  Blythe Thomson ,  Wei Lu

IPC: A61K31/4709 ,  A61P35/02 ,  C12Q1/686 ,  C12Q1/6886

Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

公开(公告)号：US11001588B2

公开(公告)日：2021-05-11

申请号：US16575456

申请日：2019-09-19

Applicant: FORMA Therapeutics, Inc.

Inventor： David R. Lancia, Jr. ,  Gary Gustafson ,  Neal Green ,  Lorna Mitchell ,  Anna Ericsson ,  David Richard

IPC: C07D401/14 ,  A61K31/4439 ,  C07D487/04 ,  A61K9/00

Abstract: The disclosure provides chemical compounds useful as activators of PKR. PKR activating compounds are useful in the treatment of disease and disorders associated with modulation of PKR and/or PKM2, such as pyruvate kinase deficiency (PKD).

公开(公告)号：US10913753B2

公开(公告)日：2021-02-09

申请号：US16077407

申请日：2017-02-13

Applicant: FORMA Therapeutics, Inc.

Inventor： David Joseph Guerin ,  Kenneth W. Bair ,  Justin A. Caravella ,  Stephanos Ioannidis, Jr. ,  David R. Lancia, Jr. ,  Hongbin Li ,  Steven Mischke ,  Pui Yee Ng ,  David Richard ,  Shawn E. R. Schiller ,  Tatiana Shelekhin ,  Zhongguo Wang

IPC: C07D519/00 ,  C07D495/04

Abstract: The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: where R1, R2, R3, R4, R5, R5′, R6, R7, X, m, and n are described herein.

公开(公告)号：US20210024508A1

公开(公告)日：2021-01-28

申请号：US17021759

申请日：2020-09-15

Applicant: FORMA Therapeutics, Inc.

Inventor： Matthew W. Martin ,  Mary-Margaret Zablocki ,  Scot Mente ,  Christopher Dinsmore ,  Zhongguo Wang ,  Xiaozhang Zheng

IPC: C07D405/14 ,  C07D221/20 ,  C07D409/14 ,  C07D413/14 ,  C07D405/06

Abstract: The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.

公开(公告)号：US10889567B2

公开(公告)日：2021-01-12

申请号：US16712951

申请日：2019-12-12

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, Jr. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  C07D401/14 ,  C07D471/04 ,  A61P35/00 ,  A61K31/47

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.

公开(公告)号：US10793554B2

公开(公告)日：2020-10-06

申请号：US16667602

申请日：2019-10-29

Applicant: FORMA Therapeutics, Inc.

Inventor： George P. Luke ,  Stephen Hubbs ,  Matthew W. Martin ,  Robert Wenslow ,  Yawei Shi ,  Jun Huang

IPC: C07D403/10

Abstract: The present disclosure reports solid forms of (4-(2-fluoro-4-(1-methyl-1H- benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone: